Frequency Therapeutics Inc (FREQ)


Stock Price Forecast

Nov. 3, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Frequency Therapeutics Inc chart...

About the Company

frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the complexity of genetic engineering. our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the u.s. alone.

Exchange

NASDAQ

Website

frequencytx.com

$13M

Total Revenue

66

Employees

$11M

Market Capitalization

-0.57

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $FREQ News

Frequency Therapeutics (NASDAQ: FREQ)

4d ago, source: The Motley Fool

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the business of developing therapeutics to activate a person’s innate regenerative potential to restore ...

Frequency Therapeutics Inc.

29d ago, source: TheStreet.com

Huang's Nvidia, one of the top performing stocks over the last year, will issue what's expected to be a whopper of an earnings report on Wednesday. The standard deduction reduces the amount of ...

Korro Bio absorbs Frequency Therapeutics in reverse biotech merger

8mon ago, source: Hosted on MSN

Venture-backed Korro Bio of Cambridge said Friday it will absorb financially struggling Frequency Therapeutics through a reverse merger in which Korro will take over Frequency’s public stock ...

Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

24d ago, source: ADVFN

2022 Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced ...

Korro Bio Inc (KRRO)

20d ago, source: Investing

Tuesday - Korro Bio Inc. (NASDAQ:KRRO ... The biotechnology company, known for its... Investing.com - Frequency Thera (NASDAQ: FREQ) reported second quarter EPS of $-0.300, $0.06 better than ...

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

18h ago, source: Business Insider

March 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology ... reductions in arrhythmia frequency and severity, and prevention of adverse fibrotic ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript

5d ago, source:

BioXcel Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.76, expectations were $-0.98. BioXcel ...

Q4 2023 Seres Therapeutics Inc Earnings Call

12d ago, source:

Rob Windsor; Head of Investor Relations and Corporate Communications; Seres Therapeutics Inc Eric Shaff; President, Chief Executive Officer, Director; Seres Therapeutics Inc Teresa Young; Executive ...

Korro Bio Inc (KRRO)

7mon ago, source: Investing

Investing.com - Frequency Thera (NASDAQ: FREQ) reported second quarter EPS of $-0.300, $0.06 better than the analyst estimate of $-0.360. Revenue for the quarter came in at $0 ...

Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

14h ago, source:

TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) PKP2 Gene Replacement Therapy Normalized Heart Rh ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcript

6d ago, source: InvestingChannel on MSN

Q4 2023 Earnings Call Transcript March 11, 2024 CytomX Therapeutics, Inc. isn't one of the 30 most popular stocks among hedge ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...